Asahi Kasei Bioprocess America (AKBA) and PeptiSystems have announced a strategic, exclusive partnership aimed at delivering a streamlined process to the peptide manufacturing industry. 

This collaboration establishes AKBA as the exclusive OEM for peptide synthesis columns to PeptiSystems, which carries out R&D, manufacturing, and supply of instruments used to synthesize peptide and oligonucleotide therapeutics.

The partnership combines AKBA’s industry knowledge and product expertise with PeptiSystems’ next-generation synthesizers. Asahi Kasei Bioprocess America will supply PeptiSystems, located in Uppsala, Sweden, with their patented THESYS ACS Ergo design, which will be optimized for peptide processing. 

Unveiled in 2024, this column offers a reduced changeover time between batches without compromising user safety and product quality. Together, the companies can provide a robust synthesis process that utilizes AKBA’s industry-leading columns and PeptiSystems’ innovative peptide flow-through synthesis systems.

The partnership between Asahi Kasei Bioprocess America and PeptiSystems will extend globally across all relevant markets, such as drug and contract manufacturing.

Asahi Kasei Bioprocess America is part of the Asahi Kasei Life Science operating segment, which includes the organization’s purification, fluid management, biosafety, and biologics development and manufacturing divisions.